Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE

Key Points

• Dimensional Fund Advisors increased its Monte Rosa Therapeutics stake by 83.2%, adding 473,005 shares to own 1.04 million shares, or 1.23% of GLUE. Institutional investors collectively hold nearly 80% of the company.
• Monte Rosa reported a quarterly loss of $0.43 per share, missing the $0.38 consensus estimate, while revenue of $8.97 million fell short of the $12.91 million forecast. The company posted a negative net margin of 560.85%.
• Analysts remain generally positive, with seven Buy ratings and a consensus “Moderate Buy” rating, although several firms lowered price targets; the average target is $28.50 versus the stock’s reported $15.88 price.

Dimensional Fund Advisors LP boosted its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 83.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,041,372 shares of the company's stock after purchasing an additional 473,005 shares during the period. Dimensional Fund Advisors LP owned 1.23% of Monte Rosa Therapeutics worth $17,125,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. AQR Capital Management LLC acquired a new stake in shares of Monte Rosa Therapeutics in the first quarter valued at $1,065,000. Goldman Sachs Group Inc. raised its stake in shares of Monte Rosa Therapeutics by 122.7% in the first quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company's stock worth $1,652,000 after acquiring an additional 196,238 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Monte Rosa Therapeutics during the first quarter worth approximately $76,000. Geode Capital Management LLC grew its stake in shares of Monte Rosa Therapeutics by 12.0% during the second quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company's stock valued at $5,071,000 after purchasing an additional 120,098 shares during the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Monte Rosa Therapeutics by 301.4% during the second quarter. American Century Companies Inc. now owns 403,045 shares of the company's stock valued at $1,818,000 after purchasing an additional 302,639 shares during the last quarter. Institutional investors own 79.96% of the company's stock.

Monte Rosa Therapeutics Trading Up 1.1%

Shares of GLUE opened at $15.88 on Friday. Monte Rosa Therapeutics, Inc. has a 12 month low of $4.12 and a 12 month high of $25.77. The firm's 50 day moving average is $20.53 and its 200-day moving average is $19.35. The stock has a market capitalization of $1.34 billion, a PE ratio of -9.02 and a beta of 1.59.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $8.97 million during the quarter, compared to the consensus estimate of $12.91 million. Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 48.30%. Equities research analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Sharon Townson sold 6,000 shares of the firm's stock in a transaction on Monday, July 6th. The stock was sold at an average price of $23.31, for a total value of $139,860.00. Following the transaction, the insider owned 67,845 shares in the company, valued at approximately $1,581,466.95. This trade represents a 8.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Filip Janku sold 5,407 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $24.50, for a total transaction of $132,471.50. Following the sale, the insider owned 60,612 shares in the company, valued at $1,484,994. This represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 81,778 shares of company stock valued at $1,768,581. Company insiders own 6.40% of the company's stock.

Analyst Ratings Changes

GLUE has been the subject of a number of research reports. Guggenheim lowered their price target on shares of Monte Rosa Therapeutics from $35.00 to $28.00 and set a "buy" rating for the company in a report on Friday. Jefferies Financial Group reissued a "buy" rating on shares of Monte Rosa Therapeutics in a research note on Monday, July 27th. Wedbush dropped their target price on Monte Rosa Therapeutics from $37.00 to $27.00 and set an "outperform" rating for the company in a research report on Monday, August 3rd. Zacks Research raised Monte Rosa Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday. Finally, Weiss Ratings raised Monte Rosa Therapeutics from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday, July 28th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $28.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company's main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.

Want to see what other hedge funds are holding GLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source